Antianemic action of the iron (IV) clathrochelate complexes

Abstract

Anemia is one of the most common non-contagious diseases of pigs. Modern antianemic drugs have several drawbacks, so finding new drugs is a pressing issue. We previously reported the results of preclinical studies of iron in rare high valence IV. This allowed us to determine, supplement, and generalize the data on clinical studies of the new drugs with the active substance iron (IV) clathrochelate. Therefore, we studied its antianemic effect on piglets. Experiments were carried out on piglets-analogues neonates, which were divided into three groups: control and two experimental groups. Piglets were kept with sows on suckling. For the purpose of prevention of iron deficiency anemia, the traditional solution of iron dextran was administered once intramuscularly to piglets of I control group. The aqueous solution of iron (IV) clathrochelate complexes was administered once intramuscularly to piglets of II experimental group. Iron (IV) clathrochelate complexes were dissolved in a solvent of rheopolyglucin and administered once intramuscularly to piglets of III experimental group. 1 mL of test solutions contained 100 mg of active substance. The investigative material were the samples of blood and serum of piglets, their liver and spleen. The experiment lasted during a 30-day period since the birth of the piglets. According to the results of the experiments, iron (IV) clatrochelate complexes which were dissolved in water for injection and rheopolyglucin had higher antianemic activity compared to the control. This is evidenced by the dynamics of probable changes in the number of erythrocytes, hemoglobin content and hematocrit, iron content in serum and its mass fraction in the blood, liver and spleen of piglets. The effectiveness of the action of iron (IV) clatrochelate complexes is demonstrated by the full supply of piglets with iron and its higher bioavailability.

Iron(iv) complexes with tetraazaadamantane-based ligands: synthesis, structure, applications in dioxygen activation and labeling of biomolecules

“…54,55 Although iron( iv ) complexes are underinvestigated in terms of bioactivity, recently promising results on their antianemic action have been reported. 56…”

“…54,55 Although iron (IV) complexes are underinvestigated in terms of bioactivity, recently promising results on their antianemic action have been reported. 56 Two strategies can be sought to access modular structures containing iron(IV)-TAAD complex 1 as a functional unit (Scheme 3). In the first one, derivatization of complex 1 is done by its direct alkylation with a suitable electrophilic agent.…”

Білковий Спектр Сироватки Крові Поросят За Впливу Препаратів Феруму

“…Вперше про синтез цієї унікальної сполуки Феруму (IV) було повідомлено Tomyn et al (2017) [19]. Ми, своєю чергою, провели низку доклінічних досліджень його гострої та хронічної токсичності на лабораторних тваринах та клінічні дослідження на поросятах [3][4][5].…”

Вплив Клатрохелату Феруму(iv) На Вміст Феруму У Деяких Внутрішніх Органах Поросят

“…Нами вже повідомлялося про результати доклінічних досліджень гострої та хронічної токсичності нової сполуки -клатрохелату Феруму у рідкісній валентності IV [8][9][10][11][12][13][14]. За клінічних досліджень даного комплексу вивчено його протианемічну ефективність в організмі поросят [15][16].…”